We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Abnormal Liver Function Test Associated with Severe SARS-CoV-2 Infection

By LabMedica International staff writers
Posted on 15 Feb 2021
COVID-19 predominantly affects the pulmonary tract causing mainly respiratory symptoms, however, involvement of other organ systems has been described, including myocarditis, acute kidney injury, neurological abnormalities and acute liver injury.

During infection with SARS-CoV-2 liver injury occurs in a relevant proportion of patients. More...
As yet, mainly elevation of aminotransferases has been described, while abnormalities of cholestatic parameters, that is, gamma-glutamyltransferase and alkaline phosphatase were reported less frequently. Liver function test (LFT) peak levels correlate with severity and/or outcome in COVID-19 patients.

Medical Scientists at the University Hospital Munich (Munich, Germany) analyzed liver function tests in a cohort of 217 patients (median age, 63 years) with SARS-CoV-2 infection and without pre-existing liver disease. Laboratory tests including liver enzymes were performed on admission and repeatedly until discharge. Values at admission as well as respective minimal and peak values were obtained via automated data extraction tools. LFT analysis included aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL) and albumin. Further analyses included C-reactive protein (CRP) and interleukin 6 (IL-6). In case the patient had been transferred from another hospital, laboratory values from the initial admission were extracted from the patients’ files.

The investigators reported that abnormal LFT at hospital admission was present in 125 (58%) patients, with a predominant elevation AST; 42%, GGT; 37% and ALT; 27%, while hypoalbuminemia was observed in 33% of the patients. Of the 217 patients, 36% required treatment in the intensive care unit (ICU) and 32% underwent mechanical ventilation, with a total fatality rate of 14.7%, mostly related to COVID-19. Elevated levels of AST, ALT, GGT as well as hypoalbuminemia were also associated with an increased risk for ICU admission with odds ratio ranging from 2.06 to 13.95. On the other hand, hyperbilirubinemia, although rare at admission, was an independent risk factor for COVID-19-related death (OR, 4.80). The team noted that when hypoalbuminemia was combined with elevation of any LFT abnormality, the risk of ICU admission was markedly increased with the highest risk observed for the combination of hypoalbuminemia and AST (OR, 46.22).

The authors concluded that there was a significant correlation of elevation of baseline LFT, including GGT, as well as hypoalbuminemia with more severe courses of SARS-CoV-2 infections. Thus, baseline hypoalbuminemia when combined with other abnormal LFT in particular with abnormal AST or GGT should be regarded as a red flag indicating a more severe course of the disease and could support clinical decisions regarding closer monitoring and intensive care of patients with COVID-19. With a cut-off of 3.55 mg/dL, which is the lower limit of normal in their laboratory institute, albumin could differentiate between less and more severe cases with a sensitivity and specificity of 80%, respectively. The study was published on January 29, 2021 in the journal GUT.

Related Links:
University Hospital Munich


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.